(GLP-1SGLT2Metformin) Rybelsus Rybelsussemaglutide **Rybelsus SNAC-N-[8-(2-)] 3mg7mg14mg Semaglutide 120cc 30 Semaglutide 24 46 BMI30 BMI27 Rybelsus 30 5002,000 SaxendaWegovy semaglutide 4-86-12 (GLP-1SGLT2Metformin)
Anti-Aging: No substantial evidence to support anti-aging claims
Medicare covered it for treating Type 2 diabetes but not for weight loss, and it cost more than $1,000 a month out-of-pocket
repeated high doses may increase risk
For type 2 diabetes management , NICE guideline NG28 recommends considering GLP-1 receptor agonists when: Triple therapy with metformin and two other oral medications is ineffective, not tolerated or contraindicated The patient has a body mass index (BMI) of 35 kg/m or higher (with lower thresholds for people from certain ethnic backgrounds), or lower BMI with specific clinical circumstances where weight loss would benefit other obesity-related comorbidities Insulin would have significant occupational implications GLP-1 therapy should only be continued beyond six months if there has been a beneficial metabolic response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0 percentage point) and weight loss of at least 3% of initial body weight
Store lyophilized Wolverine in a freezer at -20C
